Background and Aims: Long-term outcomes of early combined immunosuppression [topdown] compared to conventional management [step-up] in recently diagnosed Crohn's disease [CD] are unknown. We aimed to investigate long-term outcomes of participants of the Step-up/ Top-down-trial. Methods: Trial participants' medical records were reviewed retrospectively. For 16 semesters following the 2-year trial, we recorded: clinical activity, medication use, flares, hospitalization, surgery and fistulas. Colonoscopy reports were scored as: endoscopic remission, aphthous/small ulcers or large ulcers. The primary endpoint was the proportion of semesters in remission. Mucosal healing 2 years after treatment was associated with a reduced anti-TNF use, but not with differences in other long-term outcomes. Endoscopic remission occurred at similar rates between groups. Conclusions: Top-down treatment did not result in increased clinical remission during long-term follow-up, compared to step-up treatment. However, lower relapse rates and a reduced use of anti-TNF agents and corticosteroids were observed. No difference was found in rates of endoscopic remission, hospitalization, surgery or new fistulas. 
Introduction
Crohn's disease [CD] is a chronic, progressive disease, characterized by inflammation of the gastrointestinal tract. Most patients with CD will eventually develop stricturing or perforating complications. 1 With the currently available treatments for CD, not only controlling symptoms but also preventing disease progression is a target.
Most current treatment guidelines recommend the use of a socalled step-up approach for mild to moderate CD, which comprises initial treatment with topical or systemic corticosteroids, followed by treatment intensification if the initial therapy fails. 2, 3 It is hypothesized that combined immunosuppressive treatment early in the disease course [i.e. top-down] may alter the disease course and slow disease progression. To date, one prospective study has investigated the efficacy of relatively short-term step-up vs topdown treatment in CD. In the randomized controlled
Step-up/Topdown-trial, D'Haens et al. evaluated the efficacy of early combined immunosuppression with three infliximab infusions combined with azathioprine maintenance treatment compared with conventional management with corticosteroids, followed, in sequence, by azathioprine and infliximab when necessary in patients with newly diagnosed CD. 4 Corticosteroid-free remission rates were significantly higher in patients receiving early combined immunosuppression at weeks 14, 26 and 52. However, this effect did not persist beyond 1 year, 4 probably because of the increasing use of immunomodulators in the conventional management group. In a follow-up study of 35% of the participants 2-4 years after randomization, mucosal healing at week 104 after randomization but not treatment allocation was associated with stable, corticosteroid-free remission. 5 Indeed, mucosal healing is associated with long-term clinical remission. 6 Furthermore, it has been suggested that the early introduction of immunomodulators may change the natural history of CD. In support of this, retrospective and post-hoc analyses suggest a reduction in disease progression associated with early introduction of azathioprine. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, in two recent trials, early introduction of azathioprine was not superior to conventional management with respect to the primary outcome in newly diagnosed CD during follow-up of 1.5 years 17 and 3 years, 18 respectively. In the study by Panés et al., early azathioprine was associated with a lower risk of moderate to severe relapse. 17 Cosnes et al. found that early azathioprine was associated with a reduced occurrence of active perianal lesions and less perianal surgery. 18 To date, long-term outcomes of early combined immunosuppression vs conventional management are unknown. The aim of the current study was to evaluate the long-term outcome [i.e. 8 years] of patients with newly diagnosed CD who took part in the previously reported
Step-up/Top-down-trial.
Methods

Patient population
We performed a retrospective review of medical records of patients who were enrolled in the open-label randomized trial 'Top-down versus step-up strategies in Crohn's disease' [ Step-up/Top-down-trial; NCT00554710]. 4 Briefly, between May 2001 and January 2004, 133 patients from 18 centres in Belgium, the Netherlands and Germany, aged 16-75 years, who had been diagnosed with CD were included. The patients were naïve to corticosteroids, immunomodulators and biological agents and had clinically active disease as defined by a Crohn's Disease Activity Index [CDAI] score of > 200. Patients were randomized to either conventional management or early combined immunosuppression, and were treated for 104 weeks according to the allocated algorithm. After week 104, patients were treated at the discretion of their individual physician without any further guidance. Generally, but not necessarily, patients were treated in accordance with current guidelines. 3, 19 Eight of the 18 centres participated in an endoscopic substudy. All 49 patients [26 early combined immunosuppression, 23 conventional management] at these centres who were treated as per protocol underwent ileocolonoscopy at week 104 to assess mucosal inflammation. Complete mucosal healing was defined as a Simple Endoscopic Score for Crohn Disease (SES-CD) 20 score of 0 [i.e. the absence of ulcers and strictures in the colon and terminal ileum]. 
Data collection
Statistical analysis
The primary endpoint was the proportion of semesters in remission. Analyses were performed using SPSS 22.0.0.2 [IBM] . Comparisons between groups of not normally distributed continuous data were performed using Mann-Whitney U-tests, and of dichotomous data using Fisher's exact tests. The outcomes hospitalization, surgery, new fistula, rescue treatment and flare were analysed using time-to-event analysis. Medication exposure and disease activity were evaluated as rates per patient. Survival data are presented as Kaplan-Meier curves and comparisons between groups were performed using the Log-rank test. Event rates per patient are presented as median percentages and inter-quartile ranges [IQRs] . In case of non-informative IQRs [e.g. low event rates], 5th-95th percentiles are reported instead.
Missing data in time-to-event survival analysis were handled as follows: for semesters with no follow-up data followed by a semester with follow-up data, it was assumed that no event had occurred during the missing semesters. For semesters with no follow-up data not followed by a semester with follow-up data, patients were considered lost to follow-up.
The threshold for statistical significance was set at p < 0.05. Analyses were performed on data from all patients, except for analysis of the effect of mucosal healing status at week 104. The latter analyses were performed on data from all patients participating in the endoscopic substudy.
Results
Patient characteristics
Follow-up data were collected from 119 of the 133
Step-Up/TopDown trial participants [89%]. Eight patients were lost to follow-up prior to the start of the first follow-up semester. Six patients were not included because the treating physician did not provide follow-up data. Median duration of follow-up was 16 semesters (interquartile range [IQR] 14-16), with no difference between the two treatment arms. Patient characteristics at the start of follow-up are shown in Table 1 . Follow-up data were available for all 49 patients participating in the endoscopic substudy, 26 of whom had mucosal healing 104 weeks after randomization in the Step-Up/Top-Down trial. As reported previously, the characteristics of patients in the endoscopy substudy were comparable to those in the main study. Use of anti-TNF agents and corticosteroids per semester is shown in Figure 3 [24] [25] *Medication use in the first semester after the original trial period of 2 years was available for 53 step-up subjects and 55 top-down subjects. IQR, interquartile range; anti-TNF, anti-tumour necrosis factor. One patient in the step-up group developed a testicular carcinoma, which was successfully treated with orchiectomy. No other malignancies occurred during follow-up. One step-up patient was diagnosed with cervical dysplasia, which was successfully treated with surgery. Another stepup patient was diagnosed with high-grade oesophageal dysplasia, which was successfully treated with transthoracic resection of the oesophagus and cardia. All these patients were previously treated with azathioprine, and the two patients with dysplasia had also received infliximab. One patient in the step-up group developed a benign frontal meningioma during follow-up. Initial resection was followed by recurrence, which was successfully treated with re-resection and radiotherapy. This patient was previously treated with methotrexate, azathioprine and adalimumab. No new cases of congestive heart failure or demyelinating neurological disorders occurred during follow-up. There were no deaths during follow-up. Step-up Top-down p=0.12
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Discussion
Combined immunosuppression early in the disease course may be more effective in the short term than conventional management in patients with recently diagnosed CD. 4 In this study, we compared the long-term outcomes of these treatment algorithms in a retrospective review of medical records of the patients included in the Step-up/ Top-down-trial. 4 During a median follow-up of 8 years, no difference was found in clinical remission rate. Likewise, no differences were found in rates of endoscopic remission, hospitalization, surgery or new fistulas.
However, top-down treatment was associated with a significantly lower relapse rate as well as a longer time to relapse compared to step-up treatment. Furthermore, step-up patients were treated more frequently with corticosteroids and anti-TNF agents. Top-down treatment was associated with a more favourable endoscopic outcome, although this was not statistically significant. These results Step-up remission rate Top-down remission rate
Step-up are rate Top-down are rate Semesters Event rate indicate that the early introduction of combined immunosuppression may yield a better long-term outcome. There are several potential explanations for the lack of significant differences for many important outcomes. First, the top-down regimen consisted of only three infliximab infusions [at weeks 0, 2 and 6] followed by maintenance treatment with azathioprine or methotrexate as monotherapy. Additional infliximab infusions were given only in case of clinical deterioration, as was standard practice at the time of the study. Since then, it has been shown that scheduled maintenance treatment with infliximab is superior to episodic treatment with respect to clinical and endoscopic disease activity. 14, 21, 22 One may therefore speculate that early combined immunosuppression followed by scheduled maintenance treatment with infliximab could have resulted in a greater and/or longer lasting beneficial effect. This policy could also explain why the clinical benefit of topdown treatment was not sustained beyond week 52 in the Step-up/ Top-down-trial. 4 Secondly, relatively early introduction of immunomodulators or infliximab in the patients receiving conventional management reduced the contrast between the patient groups. At the start of follow-up, 66% of step-up patients received an immunomodulator and 15% received anti-TNF, compared to 82% and 20% of top-down patients, respectively.
Third, the absence of differences in certain outcomes among the groups may be caused by a lack of statistical power. Indeed, trends towards higher rates of infrequently occurring complications (e.g. the number of subjects who developed a new fistula [step-up 20%; top-down 12%; p = 0.20]) may reflect real, clinically relevant differences in incidence rates. Conversely, one could argue that observed statistically significant differences between groups merely reflect type 1 errors due to multiple testing. Multiple testing correction was not applied because of the exploratory nature of this study.
Combined immunosuppression early in the disease course may not alter the long-term natural history of CD if this potent antiinflammatory regimen is not maintained. Two recent trials investigating early introduction of azathioprine in CD showed convincingly that the benefit of this intervention was very limited, perhaps except for the prevention of perianal fistula formation. 17, 18 The increased incidence of disease flares in the step-up group may [partly] be explained by immunogenicity. According to the original trial protocol, all top-down-treated patients received their first doses of infliximab in combination with an immunomodulator, while this was not necessarily the case in step-up-treated patients [if infliximab was initiated after completion of the 2-year trial]. Only many years later was it shown convincingly that combination therapy is more effective than infliximab monotherapy. 23 Thus, a potentially larger proportion of patients receiving anti-TNF monotherapy in the stepup group may have led to more anti-drug antibodies, and consequently a higher proportion losing response.
The observed lower use of anti-TNF agents during long-term follow-up in top-down-treated patients is not directly relevant for current clinical practice, because it is related to the previous practice of episodic anti-TNF treatment. According to current guidelines, successful induction of remission with anti-TNF agents should be followed by scheduled maintenance treatment. 24 Furthermore, when and in whom anti-TNF treatment can be safely discontinued remains to be eludicated. 24 Nonetheless, our data indicate that perpetuated treatment with anti-TNF antibodies may not be needed in all patients.
In our study, mucosal healing 2 years after the start of treatment was associated with a reduced use of anti-TNF treatment during long-term follow-up. Other outcomes, however, did not differ significantly between patients with and without mucosal healing 2 years after the start of treatment, which is in contrast to a recent metaanalysis of 12 studies with 673 patients 6 that showed that mucosal healing is associated with an increased likelihood of long-term clinical remission. This may be related to the small number of patients participating in the endoscopic substudy [n = 49]. However, it may also indicate that the definition of mucosal healing [the complete absence of ulcers] was too restrictive. Indeed, in a post hoc analysis of the SONIC trial, endoscopic response (defined as a decrease in Crohn's Disease Endoscopic Index of Severity [CDEIS] score of ≥ 50%) was as accurate as the complete absence of ulcers in predicting corticosteroid-free clinical remission. 25 However, a recent metaanalysis showed higher odds ratios for achieving long-term clinical remission in studies using more stringent criteria. 6 Finally, mucosal healing may be a less accurate predictor of very-long-term outcome. The majority of studies included in the aforementioned meta-analysis had a follow-up time of 2 years or less. 6 To our knowledge, no study has been published to date with a comparable or longer follow-up time of mucosal healing in CD patients compared to our study.
The treatment that patients received beyond year 2 after inclusion in the Step-up/Top-down-trial was at the discretion of the treating physician. Consequently, patients' outcome may be influenced by different treatment strategies at the participating sites. However, there is no reason to assume that this has affected one treatment arm more than the other. Furthermore, subjects in both arms were evenly distributed across the participating hospitals, and thus equally exposed to the treating physician's preferences. Indeed, the comparative long-term outcome of different treatment strategies should ideally be evaluated in a study in which subjects are treated according to the allocated algorithm throughout the entire follow-up. Nonetheless, our analyses provide important information regarding the long-term outcome of step-up vs top-down treatment in CD, especially considering that the main difference between these two algorithms concerns what happens early in the disease course, rather than which treatments patients will eventually receive. This is the first study with newly diagnosed CD patients comparing the long-term outcome of early combined immunosuppression vs conventional management during a follow-up of 10 years. The most important weakness of our study is its retrospective nature, resulting in the lack of standardized clinical, endoscopic and biochemical outcome assessment.
Considering its associated lower relapse rate, early combined immunosuppression may be a preferential strategy. However, considering the associated costs and risks and the potential risk of overtreatment of patients with a potentially 'benign' disease course, a top-down approach should probably not be recommended as a universal treatment strategy for all patients with newly diagnosed CD. A useful strategy may be to institute early treatment with biologicals in high-risk patients, including those with important mucosal ulcerations, early fistulas and extensive disease.
In conclusion, long-term follow-up of patients with newly diagnosed CD who participated in the Step-up/Top-down-trial revealed a lower relapse rate and a lower use of further anti-TNF and corticosteroid treatment in top-down-treated patients. However, no difference in rates of clinical remission was observed among the two groups.
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